ProBio (1548)

Executive Summary

ProBio, a wholly-owned subsidiary of GenScript Biotech Corporation, is a global Contract Development and Manufacturing Organization (CDMO) headquartered in San Diego, USA. Founded in 2002, the company offers end-to-end services for biologics, including monoclonal antibodies, and cell & gene therapies (CGT), with capabilities spanning plasmid DNA, viral vectors, and RNA-LNP platforms. ProBio supports clients from discovery through commercialization, providing GMP manufacturing and regulatory support for IND filings across the US, Europe, and Asia. Leveraging GenScript's expertise in gene synthesis and life sciences, ProBio has established itself as a reliable partner for biopharmaceutical companies seeking integrated CMC solutions. The company's global footprint and broad technology platform position it well to capture growing demand for outsourced biologics and CGT manufacturing, particularly as the industry faces capacity constraints and increasing regulatory complexities. Looking ahead, ProBio is poised to benefit from secular tailwinds in the biologics CDMO market, driven by the expansion of gene therapies and personalized medicines. As a subsidiary of publicly traded GenScript (ticker: 1548 on the Hong Kong Stock Exchange), ProBio's financial performance is reported through GenScript's consolidated results. The company's competitive advantages include its integrated service model, proven track record in GMP manufacturing, and strategic geographic presence. However, it faces competition from established CDMOs and must continuously invest in capacity and innovation to maintain its edge. With a diversified client base and a strong parent company, ProBio is well-positioned for steady growth in the evolving biopharmaceutical landscape.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new large-scale manufacturing facility expansion70% success
• Q4 2026Key client program advances to Phase III clinical trials or BLA submission50% success
• Q2 2026Partnership with a leading cell therapy developer for commercial-scale viral vector manufacturing60% success